Landlords struggling with excess lab space in U.S. markets are finding new demand from artificial intelligence and quantum science companies, according to a report from Newmark. The Boston, Bay Area, Seattle and San Diego markets recorded 6.9 million square feet of leasing through the first nine months of this year. The number of active tenant requirements in those markets rose 63% from the mid-2025 low point.
AI companies Anthropic and Blitzy signed leases in Kendall Square this year, the report said. In the Bay Area, vacancy declined from 28.4% to 27.3%, which Newmark attributed to the outperformance of local AI and tech companies. Boston experienced meaningful AI growth, with leasing requirements in the first three quarters increasing 68% from 2025.
National lab vacancy stood at 27% in the third quarter. Rents fell in eight of the 13 largest life sciences markets. Life sciences property values have fallen 38% from their peak in 2022 and are now well below their late 2019 levels, citing the Green Street Commercial Property Price Index, Newmark said. The decline is steeper than the office market's pandemic-era drop.
Investor interest in life science assets has improved in recent quarters, but buyers remain selective, the report said. Occupiers are likely to continue to take advantage of depressed values through owner-user acquisitions. Alternative users are ramping up leasing activity within life sciences assets, helping to chip away at the overhang of space in select markets.
Biotech venture capital funding reached $11.5 billion through the third quarter of this year, already well above the levels reached in each of the four years before the pandemic. An index of publicly traded biotech companies has gained 124.6% since its April 2025 low, far outpacing the S&P 500. Merger and acquisition activity this year is the strongest it has been since 2021, the report said, indicating that Big Pharma companies are becoming far more active in the market.
Biomanufacturing has seen a significant increase, with Newmark saying the sector displays the most significant green shoots in the market. Big Pharma companies have poured hundreds of billions of dollars into U.S. manufacturing and research. Recent announcements include Eli Lilly's $6.5 billion commitment to Houston in September and BeOne's $300 million New Jersey expansion over the summer.
This positive momentum is expected to continue in the near term as select tenants seek to expand in core markets, the report said. Making substantial progress on bringing down vacancy and boosting values will require a surge in funding to the companies that lease lab space.
